Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.
[1][2] This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials (NCT03245008, NCT02683239, and NCT03161093).
[3] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.